Abatacept a Winner in JIA
(MedPage Today) -- Subcutaneous treatment effective in arthritic kids as young as 2 (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 28, 2018 Category: Pediatrics Source Type: news
Abatacept Shows Promise for RA-ILD (CME/CE)
(MedPage Today) -- Most patients ' symptoms and pulmonary function remained stable (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 1, 2018 Category: Primary Care Source Type: news
Immunotherapy drug nearly eliminates severe acute graft-versus-host disease
(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2017 Category: Cancer & Oncology Source Type: news
FDA approves Bristol-Myers Squibb ’s Orencia for active psoriatic arthritis
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb ’s Orencia for the treatment of adult patients with active psoriatic arthritis (PsA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb ’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults with active Psoriatic Arthritis (PsA)1, a chronic2,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 6, 2017 Category: Drugs & Pharmacology Source Type: news
Bristol-Myers Squibb launches prefilled syringe option for arthritis drug
Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old.
The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home.
Get the full story at our sister site, Drug Delivery Business News.
The post Bristol-Myers Squibb launches prefilled syringe option for arthritis drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pediatrics Pharmaceuticals Wall Street Beat Bristol-Myers Squibb Co. Source Type: news
Abatacept Helps Joints in Psoriatic Arthritis (CME/CE)
(MedPage Today) -- Benefits were less for skin manifestations (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 7, 2017 Category: Dermatology Source Type: news
Orencia (Abatacept) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 17, 2017 Category: Drugs & Pharmacology Source Type: news
Common Drugs Boost Diabetes Risk in RA Patients (CME/CE)
(MedPage Today) -- Hydrochloroquine, abatacept associated with reduced risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 25, 2016 Category: Cardiology Source Type: news
US as a Marker of Early Response to Abatacept in RA US as a Marker of Early Response to Abatacept in RA
Ultrasound can play an important role in assessing the early efficacy of abatacept among biologic-naive rheumatoid arthritis patients.Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
EU Clears Abatacept (Orencia) for MTX-Naive Patients With RA EU Clears Abatacept (Orencia) for MTX-Naive Patients With RA
Abatacept is indicated in combination with methotrexate for adults with highly active or progressive RA who have not previously been treated with methotrexate.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 6, 2016 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
Abatacept fails to provide benefit in relapsing-remitting MS
Results from the double-blind, randomized, placebo-controlled phase II ACCLAIM study indicate that abatacept has no effect on reducing the number of new gadolinium-enhancing lesions on MRI in... (Source: Clinical Neurology News)
Source: Clinical Neurology News - August 2, 2016 Category: Neurology Source Type: news
CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA
The EMA ' s Committee for Medicinal Products for Human Use recommended marketing authorization for abatacept in combination with methotrexate for methotrexate-naive adults with rheumatoid arthritis. < br / > < i > International Approvals < /i > (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2016 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Bristol-Myers Squibb launches Orencia ClickJect drug-device combo for rheumatoid arthritis
Bristol-Myers Squibb said today it launched the Orencia ClickJect autoinjector designed for the self-administration of Orencia to treat moderate to severe rheumatoid arthritis.
The Orencia ClickJect is designed to deliver 125 mg of subcutaneous Orencia through a push button operation with injection confirmation to reduce the possibility of user errors, the company said.
“Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector. This approv...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Bristol-Myers Squibb Co. Source Type: news
Abatacept Monotherapy vs Abatacept Plus DMARDs in RAAbatacept Monotherapy vs Abatacept Plus DMARDs in RA
What benefits do the addition of DMARDs to abatacept therapy offer patients with rheumatoid arthritis? Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
